HM97346

HM97346 is a novel, reversible small molecule inhibitor of lysine-specific demethylase 1 (LSD1), an epigenetic enzyme that plays a critical role in the pathogenesis of various malignancies, including acute myeloid leukemia (AML) and small cell lung cancer (SCLC). Developed by Hanmi Pharmaceutical, HM97346 works by inhibiting LSD1 enzymatic activity, leading to increased methylation of histone H3 lysine 4 (H3K4) and subsequent modulation of gene expression. In SCLC models, it reduces the expression of the neuroendocrine factor ASCL1. In AML models, it promotes cellular differentiation by disrupting the LSD1-GFI1 complex and inducing the expression of myeloid markers such as CD86 and CD11b. Preclinical studies have demonstrated that oral administration of HM97346 effectively inhibits tumor growth and induces apoptosis, showing significant potential both as a monotherapy and in combination with standard chemotherapeutic agents.